Sativex
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
OBJECTIVE
Sativex® is an exclusive cannabinoid-based drug approved for the treatment of spasticity due to Multiple Sclerosis (MS…
Background: Clinical trials demonstrate the efficacy and tolerability of an intervention under experimental conditions, but…
Multiple sclerosis (MS) is a progressive disease that is both disabling and highly symptomatic. Spasticity is one of the more…
Background Cannabinoid are involved in Huntington's disease (HD) and cannabinoid stimulation improves the deficits in models of…
Interest in the use of cannabinoids in a clinical setting is gradually increasing, particularly in patients where more…
Effective treatment and management of neuropathic pain has been limited. A THC:CBD endocannabinoid system modulator (Sativex…
Sativex is an oromucosal cannabinoid spray licensed as add‐on therapy for moderate to‐severe spasticity in multiple sclerosis. In…
764 VOLUME 13 | NUMBER 7 | JULY 2007 NATURE MEDICINE US scientists are waging a campaign urging the government to allow them to…
Objective: To review the legal status of medical marijuana in the US. Data Sources: Relevant publications were located using…
Symptom management in multiple sclerosis (MS) represents a primary focus for neurologists, data available in the literature on…